Supports the development of innovative cancer treatments through ADC techniques
Provides step-by-step methodologies that are readily reproducible
Features expert tips and key implementation advice to ensure successful results
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology™ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.
Authoritative and timely,
Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review
Ingrid Sassoon and Véronique Blanc
2. Antibody-Drug Conjugate Target Selection: Critical Factors
Neil H. Bander
3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization
Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal
4. Antibody-Drug Conjugate Payloads
Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke
5. Linker Technologies for Antibody-Drug Conjugates
Birte Nolting
6. In Vivo Testing of Drug-Linker Stability
Pierre-Yves Abecassis and Céline Amara
7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates
Kedan Lin, Jay Tibbitts, and Ben-Quan Shen
8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment
Miriam I. Hensgen and Bernhard Stump
9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting
James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio
10. Protocols for Lysine Conjugation
Marie-Priscille Brun and Laurence Gauzy-Lazo
11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers
Sunil Bhakta, Helga Raab, and Jagath R. Junutula
12. Enzymatic Antibody Modification by Bacterial Transglutaminase
Patrick Dennler, Roger Schibli, and Eliane Fischer
13. Formulation Development of Antibody-Drug Conjugates
William J. Galush and Aditya A. Wakankar
14. Conjugation Process Development and Scale-Up
Bernhard Stump and Jessica Steinmann
15. Methods for Conjugating Antibodies to Nanocarriers
Anil Wagh and Benedict Law
16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy
Yan Chen
17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography
Jun Ouyang
18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS
Louisette Basa
19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF
Joyce Lin and Alexandru C. Lazar
20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)
Weibing Ding
This book presents detailed protocols for key antibody-drug conjugates techniques necessary for working in the field. It provides step-by-step methodologies that are readily reproducible and features expert tips and key implementation advice.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology(TM) format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.
Authoritative and timely,
Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review.- Antibody-Drug Conjugate Target Selection: Critical Factors.- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization.- Antibody-Drug Conjugate Payloads.- Linker Technologies for Antibody-Drug Conjugates.- In Vivo Testing of Drug-Linker Stability.- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates.- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment.- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting.- Protocols for Lysine Conjugation.- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers.- Enzymatic Antibody Modification by Bacterial Transglutaminase.- Formulation Development of Antibody-Drug Conjugates.- Conjugation Process Development and Scale-Up.- Methods for Conjugating Antibodies to Nanocarriers.- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy.- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography.- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS.- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF.- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs).
Inhaltsverzeichnis
1. Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review
Ingrid Sassoon and Véronique Blanc
2. Antibody-Drug Conjugate Target Selection: Critical Factors
Neil H. Bander
3. Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization
Jay Harper, Shenlan Mao, Patrick Strout, and Adeela Kamal
4. Antibody-Drug Conjugate Payloads
Jan Anderl, Heinz Faulstich, Torsten Hechler and Michael Kulke
5. Linker Technologies for Antibody-Drug Conjugates
Birte Nolting
6. In Vivo Testing of Drug-Linker Stability
Pierre-Yves Abecassis and Céline Amara
7. Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates
Kedan Lin, Jay Tibbitts, and Ben-Quan Shen
8. Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment
Miriam I. Hensgen and Bernhard Stump
9. Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting
James E. Stefano, Michelle Busch, Lihui Hou, Anna Park, and Diego A. Gianolio
10. Protocols for Lysine Conjugation
Marie-Priscille Brun and Laurence Gauzy-Lazo
11. Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers
Sunil Bhakta, Helga Raab, and Jagath R. Junutula
12. Enzymatic Antibody Modification by Bacterial Transglutaminase
Patrick Dennler, Roger Schibli, and Eliane Fischer
13. Formulation Development of Antibody-Drug Conjugates
William J. Galush and Aditya A. Wakankar
14. Conjugation Process Development and Scale-Up
Bernhard Stump and Jessica Steinmann
15. Methods for Conjugating Antibodies to Nanocarriers
Anil Wagh and Benedict Law
16. Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy
Yan Chen
17. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography
Jun Ouyang
18. Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS
Louisette Basa
19. Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF
Joyce Lin and Alexandru C. Lazar
20. Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs)
Weibing Ding
Klappentext
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs. In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion. Written in the highly successful Methods in Molecular Biology¿ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.n Authoritative and timely, Antibody-Drug Conjugates aims to further drive ADC development and thus help toward improving cancer treatments of the future.
Supports the development of innovative cancer treatments through ADC techniques
rn
Provides step-by-step methodologies that are readily reproducible
rn
Features expert tips and key implementation advice to ensure successful results
rn
Includes supplementary material: sn.pub/extras
rn
